Early Access Program of Lazertinib in Republic of Korea
NCT04829422 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS
Last updated 2022-03-03
Summary
This early access program will be conducted to provide access to Lazertinib for adult patients with locally advanced or metastatic Non-small Cell Lung Cancer (NSCLC) with T790M mutation-positive after 1st/2nd generation EGFR TKIs Therapy.
Conditions
Interventions
- DRUG
-
Lazertinib 240 mg
The initial dose of lazertinib 240 mg (3 tablets of 80 mg lazertinib) once daily can be reduced to 160 mg once daily (2 tablets of 80 mg lazertinib) under specific circumstances
Sponsors & Collaborators
-
Yuhan Corporation
lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
NCT05862194 ·Status: COMPLETED
-
Impact of Lazertinib Dose Modification on Effectiveness and Safety
NCT05716672 ·Status: NOT_YET_RECRUITING
-
Lazertinib for Patients With NSCLC Harboring Uncommon EGFR Mutations
NCT05277701 ·Status: UNKNOWN ·Phase: PHASE2
-
The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer
NCT05167851 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
NCT05338619 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)
NCT04248829 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
NCT04075396 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC
NCT01775943 ·Status: UNKNOWN
-
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
NCT06268210 ·Status: RECRUITING ·Phase: PHASE2
-
Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib
NCT05786430 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
NCT06106802 ·Status: RECRUITING ·Phase: PHASE2
-
Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis
NCT01776684 ·Status: UNKNOWN ·Phase: NA
-
Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
NCT02431169 ·Status: TERMINATED
-
A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker
NCT06156527 ·Status: RECRUITING ·Phase: PHASE2
-
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
NCT06020989 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Feasibility of the Research for Mutation of K-ras and EGFR in CTCs From Metastatic Non Small Cells Bronchial Carcinomas
NCT01380795 ·Status: TERMINATED ·Phase: EARLY_PHASE1
-
Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutation
NCT03414814 ·Status: COMPLETED ·Phase: PHASE2
-
Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib
NCT02759835 ·Status: COMPLETED ·Phase: PHASE2
-
Survey on the Treatment Reality of Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Non-small Cell Lung Cancer(NSCLC)
NCT02475720 ·Status: COMPLETED
-
A Study of Tarceva vs. Avastin+Tarceva for Advanced NSCLC With EGFR m(+)
NCT03126799 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer
NCT00830245 ·Status: TERMINATED ·Phase: PHASE2
-
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
NCT02575560 ·Status: COMPLETED
-
The Role of Positron Emission Tomography (PET) During Erlotinib Treatment for Non-small Cell Lung Cancer
NCT01000428 ·Status: UNKNOWN
-
Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS
NCT03257124 ·Status: UNKNOWN ·Phase: PHASE2